Skip to main content
SpringerLink
Log in

Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy

  • Chapter
  • First Online:
Heart Failure: From Research to Clinical Practice

Part of the book series: Advances in Experimental Medicine and Biology ((AIM,volume 1067))

Abstract

Patients with type 1 and type 2 diabetes mellitus (T1D and T2D) show an increased incidence of heart failure (HF) even after adjustment for well established risk factors for HF such as hypertension and ischaemic heart disease. The resulting specific form of cardiomyopathy is known as diabetic cardiomyopathy” (DCM). Pathogenetic mechanisms underlying DCM are likely to be multifactorial, from altered myocardial metabolism (hyperglycaemia, hyperinsulinaemia, increased circulating fatty acids and trglycerides) to microvascular disease, autonomic neuropathy, and altered myocardial structure with fibrosis. Current medical treatment recommendations from scientific societies on HF in patients with diabetes mellitus (DM) do not differ from those for patients without DM. Regarding the effect of different hypoglycaemic drugs on HF in patients with DM, and considering the best available current evidence, the sodium-glucose-co-transporter 2 inhibitors and metformin seem to be especially advantageous regarding the effects in patients with T2D and HF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Adameova A, Dhalla NS (2014) Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 19:25

    Article  PubMed  Google Scholar 

  • Angin Y, Steinbusch LK, Simons PJ, Greulich S, Hoebers NT, Douma K, van Zandvoort MA, Coumans WA, Wijnen W, Diamant M, Ouwens DM, Glatz JF, Luiken JJ (2012) CD36 Inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem J 448:43

    Article  CAS  PubMed  Google Scholar 

  • Asrih M, Lerch R, Papageorgiou I, Pellieux C, Montessuit C (2012) Differential regulation of stimulated glucose transport by free fatty acids and PPARα or –δ agonists in cardiac myocytes. Am J Physiol Endocrinol Metab 302:E872

    Article  CAS  PubMed  Google Scholar 

  • Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998

    Article  PubMed  PubMed Central  Google Scholar 

  • Bloch A, Crittin J, Barras C, Jeannet M (1980) Hypertrophic cardiomyopathy and HLA. N Engl J Med 302:1033

    PubMed  CAS  Google Scholar 

  • Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G (2012) Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35:389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213

    Article  PubMed  Google Scholar 

  • Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93:870

    Article  PubMed  Google Scholar 

  • Caballero L, Kou S, Dulgheru R, Gonjilashvili N, Athanassopoulos GD, Barone D, Baroni M, Cardim N, Gomez de Diego JJ, Oliva MJ, Hagendorff A, Hristova K, Lopez T, Magne J, Martinez C, de la Morena G, Popescu BA, Penicka M, Ozyigit T, Rodrigo Carbonero JD, Salustri A, Van De Veire N, Von Bardeleben RS, Vinereanu D, Voigt JU, Zamorano JL, Bernard A, Donal E, Lang RM, Badano LP, Lancellotti P (2015) Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging 16:1031

    PubMed  Google Scholar 

  • Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162:938

    Article  CAS  PubMed  Google Scholar 

  • Cesario DA, Brar R, Shivkumar K (2006) Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin N Am 35:601

    Article  CAS  Google Scholar 

  • Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 314:1547–1552

    Article  CAS  PubMed  Google Scholar 

  • Debono M, Cachia E (2007) The impact of Cardiovascular Autonomic Neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci 132:1

    Article  PubMed  Google Scholar 

  • Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101:2271

    Article  CAS  PubMed  Google Scholar 

  • Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B, Sibilio G (2005) Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 22:1720

    Article  PubMed  Google Scholar 

  • Diamant M, Lamb HJ, Smit JW, de Roos A, Heine RJ (2005) Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. Diabetologia 48:1669

    Article  CAS  PubMed  Google Scholar 

  • Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533

    Article  Google Scholar 

  • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive Investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366:1279

    Article  CAS  Google Scholar 

  • Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, Pignonblanc PG, Croisille P, Ovize M, Groisne L, Moulin P, Gillebert TC, Derumeaux G (2011) Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 24:1268

    Article  PubMed  Google Scholar 

  • Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6:395

    Article  CAS  PubMed  Google Scholar 

  • Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH (2005) Screening for heart disease in diabetic subjects. Am Heart J 149:349

    Article  PubMed  Google Scholar 

  • Fitchett DH, Udell JA, Inzucchi SE (2017) Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19:43

    Article  CAS  PubMed  Google Scholar 

  • Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, Investigators SENIORS (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215

    Article  CAS  PubMed  Google Scholar 

  • Frangogiannis NG (2014) The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11:255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • From AM, Scott CG, Chen HH (2009) Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol 103:1463

    Article  PubMed  PubMed Central  Google Scholar 

  • Goldberg IJ, Trent CM, Schulze PC (2012) Lipid metabolism and toxicity in the heart. Cell Metab 15:805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, Investigators CHARM (2003) Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772

    Article  CAS  PubMed  Google Scholar 

  • Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group (2015) Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232

    Article  CAS  PubMed  Google Scholar 

  • Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Køber L, Torp-Pedersen C (2004) Danish Investigatord of Arrhythmia and Mortality on Dofetilde Study Group. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43:771

    Article  PubMed  Google Scholar 

  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1998) UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837

    Article  Google Scholar 

  • Inzucchi SE, Masoudi FA, McGuire DK (2007) Metformin therapy in patients with type 2 diabetes complicated by heart failure. Am Heart J 154:e45

    Article  PubMed  Google Scholar 

  • Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jadhav A, Tiwari S, Lee P, Ndisang JF (2013) The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther 345:239

    Article  CAS  Google Scholar 

  • Jarnert C, Landstedt-Hallin L, Malmberg K, Melcher A, Ohrvik J, Persson H, Rydén L (2009) A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail 11:39

    Article  PubMed  Google Scholar 

  • Jensen MT, Sogaard P, Andersen HU, Bech J, Hansen TF, Galatius S, Jørgensen PG, Biering-Sørensen T, Møgelvang R, Rossing P, Jensen JS (2014) Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia 57:672

    Article  CAS  PubMed  Google Scholar 

  • Jørgensen PG, Jensen MT, Mogelvang R, von Scholten BJ, Bech J, Fritz-Hansen T, Galatius S, Biering-Sørensen T, Andersen HU, Vilsbøll T, Rossing P, Jensen JS (2016) Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. Diab Vasc Dis Res 13:321

    Article  CAS  PubMed  Google Scholar 

  • Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ (2011) Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306:856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study JAMA 241:2035

    PubMed  CAS  Google Scholar 

  • Kawata T, Daimon M, Miyazaki S, Ichikawa R, Maruyama M, Chiang SJ, Ito C, Sato F, Watada H, Daida H (2015) Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 14:98

    Article  PubMed  PubMed Central  Google Scholar 

  • Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374:1321

    Article  CAS  PubMed  Google Scholar 

  • Khatter JC, Sadri P, Zhang M, Hoeschen RJ (1996) Myocardial angiotensin II (Ang II) receptors in diabetic rats. Ann N Y Acad Sci 793:466

    Article  CAS  PubMed  Google Scholar 

  • Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543

    Article  CAS  PubMed  Google Scholar 

  • Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR (2007) CD36 Expression contributes to age-induced cardiomyopathy in mice. Circulation 116:2139

    Article  CAS  PubMed  Google Scholar 

  • Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD (2014) Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384:2235

    Article  CAS  PubMed  Google Scholar 

  • Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Med 130:S40

    Article  CAS  Google Scholar 

  • Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, Clarke W, Sabharwal N, Antoniades C, Schneider J, Robson M, Clarke K, Karamitsos T, Rider O, Neubauer S (2016) Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol 68:53

    Article  PubMed  PubMed Central  Google Scholar 

  • Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, Wong E, Sohani ZN, Bala MM, Rios LP, Malaga G, Ebrahim S, Shen J, Zhang L, Zhao P, Chen Q, Wang Y, Guyatt GH, Sun X (2016) Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord 16:91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S (2012) The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 55:2946

    Article  CAS  Google Scholar 

  • Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB (2003) Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol 41:2022

    Article  CAS  PubMed  Google Scholar 

  • Lopaschuk GD, Tahiliani AG, Vadlamudi RV, Katz S, McNeill JH (1983) Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am J Phys 245:H969–H976

    CAS  Google Scholar 

  • Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U (2009) Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 30:850

    Article  PubMed  PubMed Central  Google Scholar 

  • Masoudi FA, Inzucchi SE (2007) Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99:113B

    Article  CAS  PubMed  Google Scholar 

  • McAlister FA, Eurich DT, Majumdar SR, Johnson JA (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10:703

    Article  CAS  PubMed  Google Scholar 

  • McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B (2003) CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 5:261

    Article  CAS  PubMed  Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993

    Article  CAS  PubMed  Google Scholar 

  • Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137

    Article  PubMed  PubMed Central  Google Scholar 

  • Mythri S, Rajeev H (2015) Left Ventricular Diastolic Dysfunction (LVDD) & Cardiovascular Autonomic Neuropathy (CAN) in Type 2 Diabetes Mellitus (DM): A Cross-Sectional Clinical Study. J Clin Diagn Res 9:OC18

    Google Scholar 

  • Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative (2017 Jun 12) Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1611925

  • Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2003) American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108:2941

    Article  Google Scholar 

  • Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, Siebelink HM, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ (2010) Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 122:2538

    Article  Google Scholar 

  • Orea-Tejeda A, Colín-Ramírez E, Castillo-Martínez L, Asensio-Lafuente E, Corzo-León D, González-Toledo R, Rebollar-González V, Narváez-David R, Dorantes-García J (2007) Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Investig Clin 59:103

    CAS  Google Scholar 

  • ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319

    Article  CAS  Google Scholar 

  • Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, Zuithoff NP, Rutten FH, Hoes AW (2011) Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 13:518

    Article  PubMed  Google Scholar 

  • Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DL DM, Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651

    Article  CAS  PubMed  Google Scholar 

  • Park TS, Goldberg IJ (2012) Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin 8:633

    Article  PubMed  PubMed Central  Google Scholar 

  • Pepino MY, Kuda O, Samovski D, Abumrad NA (2014) Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr 34:281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pérez A, Wägner AM, Carreras G, Giménez G, Sánchez-Quesada JL, Rigla M, Gómez-Gerique JA, Pou JM, de Leiva A (2000) Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch Intern Med 160:2756

    Article  PubMed  Google Scholar 

  • Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309

    Article  CAS  PubMed  Google Scholar 

  • Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24:5

    Article  CAS  PubMed  Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891

    Article  PubMed  Google Scholar 

  • Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B (1977) Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60:884

    Article  CAS  PubMed  Google Scholar 

  • Revuelta-López E, Cal R, Julve J, Rull A, Martínez-Bujidos M, Perez-Cuellar M, Ordoñez-Llanos J, Badimon L, Sanchez-Quesada JL, Llorente-Cortés V (2015) Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation. Int J Biochem Cell Biol 65:257

    Article  CAS  PubMed  Google Scholar 

  • Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54:1524

    Article  CAS  Google Scholar 

  • Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A, Pivodic A, Gudbjörnsdottir S, Lind M (2015) Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 3:876

    Article  PubMed  Google Scholar 

  • Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595

    Article  CAS  PubMed  Google Scholar 

  • Sánchez-Quesada JL, Vinagre I, De Juan-Franco E, Sánchez-Hernández J, Bonet-Marques R, Blanco-Vaca F, Ordóñez-Llanos J, Pérez A (2013) Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol 12:112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317

    Article  CAS  PubMed  Google Scholar 

  • Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5:333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529

    Article  CAS  PubMed  Google Scholar 

  • Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM (2003 May 7) Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 41(9):1510–1518

    Article  PubMed  Google Scholar 

  • Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332

    Article  CAS  PubMed  Google Scholar 

  • SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685

    Article  Google Scholar 

  • Standl E, Schnell O, McGuire DK (2016) Heart failure considerations of Antihyperglycemic medications for type 2 diabetes. Circ Res 118:1830

    Article  CAS  PubMed  Google Scholar 

  • Steinbusch LK, Schwenk RW, Ouwens DM, Diamant M, Glatz JF, Luiken JJ (2011) Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol Life Sci 68:2525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Swedberg K, Komajda M, Bӧhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885

    Article  CAS  PubMed  Google Scholar 

  • Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731

    Article  PubMed  PubMed Central  Google Scholar 

  • Vaur L, Gueret P, Lievre M, Chabaud S, Passa P (2003) DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 26:855

    Article  PubMed  Google Scholar 

  • Velez M, Kohli S, Sabbah HN (2014) Animal models of insulin resistance and heart failure. Heart Fail Rev 19:1

    Article  CAS  PubMed  Google Scholar 

  • Vinagre I, Sánchez-Quesada JL, Sánchez-Hernández J, Santos D, Ordoñez-Llanos J, De Leiva A, Pérez A (2014) Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol 13:34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Rydén L (2004) Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 90:1483

    Article  Google Scholar 

  • von Scholten BJ, Hasbak P, Christensen TE, Ghotbi AA, Kjaer A, Rossing P, Hansen TW (2016) Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia 59:371

    Article  CAS  Google Scholar 

  • Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108:977

    Article  PubMed  Google Scholar 

  • Westermann D, Rutschow S, Jäger S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschöpe C (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56:641

    Article  CAS  PubMed  Google Scholar 

  • WRITING COMMITTEE MEMBERS, ACC/AHA TASK FORCE MEMBERS (2016) 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 22:659

    Article  Google Scholar 

  • Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M (2007) Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153:1055

    Article  CAS  PubMed  Google Scholar 

  • Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067

    Article  CAS  PubMed  Google Scholar 

  • Zhao XY, Hu SJ, Li J, Mou Y, Chen BP, Xia Q (2006) Decreased cardiac sarcoplasmic reticulum Ca2+ −ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats. J Physiol Biochem 62:1

    Article  CAS  PubMed  Google Scholar 

  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work wfrom Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain; CIBERDEM, a research network initiative of Instituto de Salud Carlos III, Spain and from la Fundació Marató TV3 (Grant number 201602.30.31) of Spain.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Nutrition Service, University Hospital Germans Trias i Pujol, Badalona, Spain

    Núria Alonso & Dídac Mauricio

  2. Centro de Investigación Biomédica Sobre Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain

    Núria Alonso & Dídac Mauricio

  3. Institut de Recerca Biomèdica de Lleida, Lleida, Spain

    Núria Alonso & Dídac Mauricio

  4. Cardiology Service, Heart Failure Unit. University Hospital Germans Trias i Pujol, Badalona, Spain

    Pedro Moliner

  5. Department of Medicine, Barcelona Autonomous University (UAB), Barcelona, Spain

    Núria Alonso, Pedro Moliner & Dídac Mauricio

Authors
  1. Núria Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro Moliner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dídac Mauricio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Núria Alonso .

Editor information

Editors and Affiliations

  1. Department of Clinical Sciences and Education, Karolinska Institutet, Stockholm, Sweden

    Md. Shahidul Islam

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Alonso, N., Moliner, P., Mauricio, D. (2017). Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. In: Islam, M. (eds) Heart Failure: From Research to Clinical Practice. Advances in Experimental Medicine and Biology(), vol 1067. Springer, Cham. https://doi.org/10.1007/5584_2017_105

Download citation

  • DOI: https://doi.org/10.1007/5584_2017_105

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78279-9

  • Online ISBN: 978-3-319-78280-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation